MF Analyser

Bajaj Finserv Healthcare Fund vs DSP Healthcare Fund

Bajaj Finserv Healthcare Fund and DSP Healthcare Fund are both Pharma & Healthcare Funds. As of 5 Nov 2026 (Direct plan, Growth option): 3-year CAGR — vs +22.27%, 5-year CAGR — vs +16.68%, volatility 16.34% vs 14.15%, maximum drawdown −15.68% vs −21.74%. Their portfolios overlap by 26% (7 stocks held by both).

Showing the Direct plan, Growth option. Portfolio, sector and market-cap figures are the same for every plan and option of a fund.

Key facts

Bajaj Finserv HealthcareDSP Healthcare
Fund houseBajaj Finserv Mutual FundDSP Mutual Fund
Compared asPharma & Healthcare FundsPharma & Healthcare Funds
NAV₹12.2020₹51.5580
NAV date5 Nov 20264 Nov 2026
Launched (first NAV)30 Dec 20243 Dec 2018
Track record1.8 yrs7.9 yrs
Fund size (AUM)₹405 Cr₹3,750 Cr
Securities held3432
Portfolio as of30 Sep 202630 Sep 2026
Fund pageFull record →Full record →

Returns

Bajaj Finserv HealthcareDSP Healthcare
1 month+3.59%+3.74%
3 months+2.69%+3.17%
6 months+16.60%+15.31%
1 year+20.98%+18.20%
3 years (CAGR)—+22.27%
5 years (CAGR)—+16.68%
7 years (CAGR)—+25.02%
10 years (CAGR)——
Since launch (CAGR)+10.89%+22.92%
SIP return (XIRR, 5 years) ⓘ—+19.79%

Up to one year: absolute return. Beyond one year: CAGR. Computed from each fund's own NAV history (AMFI), measured to the latest NAV.

Calendar-year returns

Bajaj Finserv HealthcareDSP Healthcare
2026 (year to date)+24.48%+18.43%
2025−2.94%−4.55%
2024—+42.61%
2023—+36.80%
2022—−6.50%
2021—+25.11%

Risk

Bajaj Finserv HealthcareDSP Healthcare
Volatility (annualised) ⓘ16.34%14.15%
Downside volatility ⓘ11.52%8.42%
Sharpe ratio ⓘ0.271.12
Sortino ratio ⓘ0.381.88
Maximum drawdown ⓘ−15.68%−21.74%
Recovery from that fall9 months1 months
Current fall from peak−1.83%−0.26%
Rolling 1-year return: worst−4.21%−14.02%
Rolling 1-year return: median+12.71%+20.41%
Rolling 1-year return: best+27.12%+97.11%
Share of 1-year periods with a loss10.90%18.69%

Against each fund's benchmark

Bajaj Finserv HealthcareDSP Healthcare
Beta ⓘ0.790.68
Alpha (Jensen's, annualised) ⓘ+8.04%+11.49%
R² ⓘ63.0350.63
Upside capture116.40%109.16%
Downside capture72.47%49.05%
Tracking error10.73%11.68%
Information ratio0.891.00
Treynor ratio3.5222.47

Portfolio

Asset mix

Bajaj Finserv HealthcareDSP Healthcare
Equity95.56%83.95%
Cash & equivalents3.13%6.74%
Mutual Fund Units1.31%0.00%
Foreign Securities0.00%9.31%

Market-cap split (share of fund assets)

Bajaj Finserv HealthcareDSP Healthcare
Large Cap30.33%24.86%
Mid Cap28.79%14.16%
Small Cap36.44%42.73%
Unclassified0.00%2.20%

Concentration

Bajaj Finserv HealthcareDSP Healthcare
Top 10 holdings59.23%59.35%
Effective number of stocks ⓘ21.722.7
Securities held3432

Portfolio overlap: 26%

7 companies are held by both funds; by weight, 26% of the two portfolios is the same. That is a moderate overlap.

Held by bothBajaj Finserv HealthcareDSP Healthcare
Sun Pharmaceutical Industries Limited8.96%7.44%
Apollo Hospitals Enterprise Limited5.51%6.07%
Divi's Laboratories Limited9.75%4.17%
Alkem Laboratories Limited2.96%4.75%
IPCA Laboratories Limited2.40%8.13%
Vijaya Diagnostic Centre Limited2.19%2.36%
Cipla Limited1.33%7.18%

Top 10 holdings

Bajaj Finserv Healthcare

  1. Divi's Laboratories Limited9.75%
  2. Sun Pharmaceutical Industries Limited8.96%
  3. Piramal Pharma Limited6.36%
  4. Rubicon Research Limited6.08%
  5. Aurobindo Pharma Limited6.03%
  6. Apollo Hospitals Enterprise Limited5.51%
  7. Torrent Pharmaceuticals Limited4.78%
  8. Emcure Pharmaceuticals Limited4.03%
  9. Laurus Labs Limited3.91%
  10. Neuland Laboratories Limited3.82%

DSP Healthcare

  1. IPCA Laboratories Limited8.13%
  2. Sun Pharmaceutical Industries Limited7.44%
  3. Cipla Limited7.18%
  4. Sai Life Sciences Limited6.52%
  5. Gland Pharma Limited6.15%
  6. Apollo Hospitals Enterprise Limited6.07%
  7. Globus Medical Inc5.15%
  8. Alkem Laboratories Limited4.75%
  9. Divi's Laboratories Limited4.17%
  10. Cohance Lifesciences Limited3.79%

Sector exposure

Bajaj Finserv HealthcareDSP Healthcare
Pharmaceuticals & Biotechnology73.73%65.75%
Healthcare Services15.62%17.84%
Healthcare Equipment & Supplies0.00%5.60%
Food Products2.20%0.00%
Health Care Equipment0.00%1.95%
Consumer Durables1.88%0.00%
Unclassified1.31%0.00%
Chemicals & Petrochemicals1.17%0.00%
Foreign Security0.00%1.10%
Insurance0.75%1.02%
Fertilizers & Agrochemicals0.21%0.00%

Questions people ask

What is the difference between Bajaj Finserv Healthcare and DSP Healthcare returns?

As of 5 Nov 2026, Direct plan Growth option: 1-year return +20.98% vs +18.20%; 3-year CAGR — vs +22.27%; 5-year CAGR — vs +16.68%; 10-year CAGR — vs —. Past returns do not indicate future returns.

How do Bajaj Finserv Healthcare and DSP Healthcare compare on risk?

Volatility (36 monthly returns, annualised) 16.34% vs 14.15%; Sharpe ratio 0.27 vs 1.12; Sortino ratio 0.38 vs 1.88; maximum drawdown −15.68% vs −21.74%; beta 0.79 vs 0.68.

How much do Bajaj Finserv Healthcare and DSP Healthcare overlap?

By weight, 26% of the two portfolios is invested in the same companies; 7 stocks are held by both, the largest shared positions being Sun Pharmaceutical Industries Limited, Apollo Hospitals Enterprise Limited, Divi's Laboratories Limited. Based on the portfolios disclosed for Sep 2026 and Sep 2026.

What is the large, mid and small cap split of Bajaj Finserv Healthcare and DSP Healthcare?

Bajaj Finserv Healthcare: large cap 30.3%, mid cap 28.8%, small cap 36.4%. DSP Healthcare: large cap 24.9%, mid cap 14.2%, small cap 42.7% (share of the fund's assets, from its latest disclosed portfolio).

Is this a recommendation to choose one of these funds?

No. This page places the published figures of both funds side by side. It does not rank, rate or recommend either fund; which one suits an investor depends on their goals, horizon and risk tolerance.

More comparisons

All Pharma & Healthcare Funds comparisons → · Compare up to six funds yourself → · Every fund in this category → · All comparisons →

Sources: NAV from AMFI; returns, risk and ratios computed by MF Analyser from each fund's NAV history (risk on 36 monthly returns, risk-free rate 6.5%); benchmark ratios against each fund's benchmark total-return index; portfolios from each fund house's monthly disclosure. Returns and ratios as of 5 Nov 2026. IDCW options show no return or risk figures because payouts reduce the NAV and AMFI's file carries no payout history to add back. This page compares published figures only — it does not rank, rate or recommend either fund. Past performance does not indicate future returns; mutual fund investments are subject to market risks.